Somewhere this week, in a memory clinic waiting room, a daughter is going to ask the question that every family asks after the scan and the blood test and the long pause: is there anything else? Is anything coming? The honest answer is a number, and once a year it gets counted. On January 1, 2026, according to the tenth annual pipeline audit by Jeffrey Cummings of the University of Nevada, Las Vegas and colleagues, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions on May 5, 2026, there were 158 drugs being tested in 192 registered Alzheimer's trials worldwide. That is up from 182 trials and 138 drugs a year earlier, and from 164 trials and 127 drugs in 2024. The paper is a review of what is registered on clinicaltrials.gov, not a verdict on any of it.

Break the census open and the shape of the field appears. Fifty-four trials are testing 36 drugs in Phase 3, the large late-stage studies that regulators read; 89 trials are testing 84 drugs in Phase 2; 49 trials are testing 45 drugs in Phase 1. Twelve of the 192 are long-term extensions, following people who were already treated in an earlier study. To fill every one of these trials, the authors calculate, takes 54,728 participants: 38,417 of them in Phase 3 alone, 13,961 in Phase 2, 2,350 in Phase 1. That figure is the quiet engine of the whole enterprise. Every drug on the list is waiting on volunteers, and every month of slow recruitment is a month added to an answer.

The biology being chased has widened, which is the most consequential thing in the report for anyone whose Alzheimer's does not fit the narrow profile the approved antibodies were built for. Small molecule disease targeting therapies make up 39 percent of the agents and biologic disease targeting therapies 34 percent, with 18 percent aimed at cognitive symptoms and 10 percent at neuropsychiatric symptoms such as agitation and psychosis. Amyloid accounts for 18 percent of the pipeline; in the report's own decade-long comparison, amyloid targeting agents have fallen from around a third of the pipeline in 2016, while drugs aimed at inflammation and immune dysfunction have risen from about 6 percent to about 18 percent. "It is clear that Alzheimer's is a complex disease with many contributing elements," Cummings said in the university's announcement of the paper. The report counts 17 distinct disease processes with at least one drug in trials against them.

A third of the candidates are not new molecules at all. Fifty-six agents, 35 percent of the total, are repurposed drugs already approved for something else, appearing in 73 of the active trials. That approach is cheaper and faster and starts with a known safety record, and it is why families sometimes read a familiar pharmacy-shelf name in an Alzheimer's headline. It is also where the caution has to be loudest: a drug being in a trial is a question being asked, not an answer, and nothing in this census tells anyone that a repurposed agent helps Alzheimer's. Who pays matters too. The biopharmaceutical industry sponsors 59 percent of all the trials and 72 percent of the Phase 3 trials, meaning the decision about which questions reach the decisive stage sits largely with companies. Cummings discloses consulting relationships with a long list of them, including Biogen, Eisai, Lilly, Novo Nordisk and Roche.

Where are these trials, and who is in them? Of the 177 trials with location data, 65 (37 percent) run only in North America. Among Phase 3 trials, six run only in North America, 12 only outside it, and 31 in both regions. The trials also reach further along the continuum than the approved treatments do: 10 trials (5 percent) enrol people with no cognitive symptoms but biomarker or genetic evidence of Alzheimer's, 67 (35 percent) enrol people with mild cognitive impairment due to Alzheimer's, 102 (53 percent) enrol people with mild Alzheimer's dementia, and 63 (33 percent) include people at the moderate or severe stage, the group most often left out. Half of active trials now use a biomarker to decide eligibility, which is the practical reason a research nurse may want a spinal fluid or blood result before a family gets an answer about enrolling.

What makes this year's tally more than bookkeeping is the calendar attached to it. The report notes that eight Phase 3 trials reach their primary completion date during 2026 and 29 Phase 2 trials will finish, the densest cluster of Alzheimer's readouts the field has ever lined up in a single year. Some of those results will be disappointing; that is what a pipeline looks like when it is working honestly. And for scale, set 54,728 against the roughly 7.4 million Americans aged 65 and over estimated to be living with Alzheimer's, the figure the university cited alongside the report. The census is a map of effort, drawn once a year. It is not a map of what is available at the pharmacy counter this afternoon.